1. Home
  2. |Insights
  3. |AI and Health Care: Perspectives from Policymakers and Movers in the Industry

AI and Health Care: Perspectives from Policymakers and Movers in the Industry

Event | 11.02.23, 4:00 PM EDT - 7:00 PM EDT

Address

Crowell & Moring
1001 Pennsylvania Avenue, NW
Washington, DC 20004

Register Here

Artificial Intelligence (AI) and Machine Learning (ML) systems and technologies have quickly become one of the greatest technological leaps of the 21st century, bringing new innovations across all industries, including in health care. In the U.S. and across the globe, healthcare organizations continue to develop and incorporate AI/ML technologies, with the goals of improving health outcomes and management, improving operations, reducing administrative burden for clinicians, and supporting patient engagement. 

Crowell invites you to an in-person roundtable discussion on Thursday, November 2nd at 4 PM EST where we will dive into AI and health care from both the domestic and international perspectives. Consisting of two panels, the roundtable will bring representatives from the public and private sector to discuss:

  • Current U.S. policy developments to regulate AI in healthcare settings, including a discussion of recent proposals from federal health agencies
  • Recent actions by the United States and European Union and to govern use of AI in health care
  • Companies’ current and future use of evolving health AI/ML technologies and the impact of pending regulations on AI technology
  • How organizations can support ethical use and regulatory compliance when using health AI systems and technologies

Panel 1 | Policy Developments Governing Use of AI in Health Care at Home and Abroad

  • Nigel Cory, Associate Director, Trade Policy, Information Technology and Innovation Foundation
  • Danielle Carnival, Deputy Assistant to the President for the Cancer Moonshot and Dep. Dir. For Health Outcomes, OSTP, The White House

Panel 2 | Company Perspectives: Current and Future Uses of AI and Policy Implications

  • Dale Kadlec, Lead Counsel, US Health and Life Sciences, Microsoft
  • Ashley Southerland, Vice President, Deputy General Counsel, Homeward Health
  • Christian Wickert, Head of Global Digital Policy, Merck KGaA, Darmstadt, Germany

Moderators 

  • Jodi Daniel, Partner & Crowell Health Solutions Managing Director, Crowell & Moring
  • Patricia Wu, Vice President and Managing Director, Crowell & Moring International 
  • Aaron Cummings, Partner, Crowell & Moring Government Affairs 
  • Roma Sharma, Counsel & Crowell Health Solutions Director, Crowell & Moring

We hope you will join us in person for this timely discussion.  Following the roundtable, Crowell will host a networking reception on our terrace.

At this time, we request that no person from the media register for this event.

Questions—For questions about this event, please contact Arielle Carani.

For more information, please visit these areas: Crowell Health Solutions, Health Care, Artificial Intelligence

Participants

Insights

Event | 02.20.25

Has the Buss Stopped? Recoupment Today

Has the Buss Stopped? Recoupment Today: In 1997, the California Supreme Court decided Buss v. Superior Court. In Buss, the court concluded that a liability insurer that defended a mixed action could seek reimbursement from the insured for the defense costs associated with the claims that were not even potentially covered. Since then, numerous courts have held that insurers are entitled to recoup their defense costs associated with uncovered claims or causes of action. On the other hand, a significant number of courts have rejected insurers’ right to recoupment, at least in the absence of a policy provision granting the insurer that right. Some commentators have even suggested that the current judicial trend might be away from permitting insurers to recoup their defense costs. Is that correct? Has the Buss stopped? This panel of coverage experts will analyze insurers’ claimed right to recoupment today, and offer their perspectives on what the law on recoupment should perhaps be and might be in the future.

View All Insights